Radient Technologies Announces Receipt of Cannabis Research Licence for Human Administration Trials and Sensory and Taste Evaluation of Cannabis Products

This Post Was Syndicated Under License Via QuoteMedia

Edmonton, Alberta–(Newsfile Corp. – November 27, 2020) – Radient Technologies Inc. (TSXV: RTI) (OTCQX: RDDTF) (“Radient” or the “Company”), is pleased to announce that it has received its Cannabis Research Licence under Health Canada’s Cannabis Act and Cannabis Regulations. This license permits Radient to expand its research activities by allowing the controlled administration of cannabis to human subjects to complete a comprehensive evaluation of sensory preferences.

A human sensory panel is an extremely valuable tool to include in product development and quality programs. It will now form an integral part of Radient’s R&D and product development and innovation activities by including the ability to evaluate our cannabis extracts, concentrates, edibles and topicals for reactions of human subjects to the smell, sight, taste and touch at the product development stage.

“Radient is committed to the highest standards of product safety and quality for our customers. This research licence greatly enhances our formulations and product development capabilities to study the effects of product ingredients and flavours to understand what drives consumer preferences for cannabis products. This will undoubtedly enhance innovation and drive value for our clients through superior formulations and reduced time to market,” said Dr. Anna Bakowska, Radient’s Director of Formulations and Product Development.

This new tool will improve the inherent quality of cannabis product offerings by complementing the stringent internal manufacturing quality systems currently in place, ensuring that all products continue to meet consumers’ expectations. This is in addition to Radient’s proprietary MAP continuous extraction process that has proven to generate high recoveries (> 95%) of active compounds from the cannabis plant.

Dreamy CBD

Enter Your E-mail Address To Subscribe

* indicates required

Radient announced on November 25, 2020 exclusive rights to Dreamy CBD brands (“Dreamy“) for the Canadian market to expand its production of high quality CBD products. With the grant of the Cannabis Research License, Radient will continue to drive innovation in the Health and Wellness space by using data gathered by sensory evaluations. Dreamy is a lifestyle brand with over a decade of experience in consumer preferences in holistic and plant-based wellness products. Dreamy CBD’s market knowledge will complement Radient’s efforts in understanding blends and profiles of CBD products to cater to this growing demand for CBD offerings. Radient clarifies that this is a licensing agreement, and not a partnership as stated in the November 25, 2020 announcement, and so meets all regulatory requirements as laid out by Health Canada’s Cannabis Act and Cannabis Regulations.

About Radient

Radient Technologies is an innovative science-based company that is a commercial manufacturer of high quality cannabinoid-based formulations, ingredients and products. Utilizing a proprietary extraction and downstream processing platform that recovers up to 99% of cannabinoids from the cannabis plant, Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety. Radient also has a science lab that is focused on innovation with expertise in formulations and technologies offering unique solutions in the cannabis and wellness space. Please visit www.radientinc.com for more information.

SOURCE: Radient Technologies Inc.

For further information please contact:

Radient – Investor Relations, [email protected]

Forward Looking Information:

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.


To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69078

If You Liked This Article Click To Share